Metrikler
Yayın
177
Açık Erişim
10
BM Sürdürülebilir Kalkınma Amaçları
Eğitim Bilgileri
2016 - 2019
2016 - 2019Tıpta Yandal Uzmanlık
Trakya Üniversitesi, Türkiye
2011 - 2015
2011 - 2015Tıpta Uzmanlık
İstanbul Medeniyet Üniversitesi, Türkiye
2003 - 2010
2003 - 2010Lisans
Marmara Üniversitesi, Tıp Fakültesi, Türkiye
Yaptığı Tezler
2015
2015Tıpta Uzmanlık
Ailevi akdeniz ateşine ikincil gelişen amiloidozda kardiyovasküler bulguların değerlendirilmesi
Diğer (Kurumlar,hastaneler Vb.)
Araştırma Alanları
Tıp
Onkoloji
Sağlık Bilimleri
Akademik Ünvanlar / Görevler
2021 - 2021
2021 - 2021Doç. Dr.
Marmara Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü
Akademi Dışı Deneyim
2019 - 2021
2019 - 2021Tıbbi Onkoloji Uzmanı-Edirne Sultan I. Murat Devlet Hastanesi
SAĞLIK BAKANLIĞI, Tıbbi Onkoloji Uzmanı-Edirne Sultan I. Murat Devlet Hastanesi
2015 - 2016
2015 - 2016İÇ HASTALIKLARI UZMANI
İSTANBUL GÖZTEPE EĞİTİM VE ARAŞTIRMA HASTANESİ, İÇ HASTALIKLARI UZMANI
2010 - 2011
2010 - 2011PENDİK 3. NOLU İSTASYON BİRİMİ
İSTANBUL İL AMBULANS SERVİSİ BAŞHAKEMLİĞİ (ANADOLU), PENDİK 3. NOLU İSTASYON BİRİMİ
Makaleler
Tümü (137)
SCI-E, SSCI, AHCI (91)
SCI-E, SSCI, AHCI, ESCI (114)
ESCI (16)
Scopus (107)
TRDizin (34)
Diğer Yayınlar (15)
2025
20251. Clinical and Demographic Features in Malignant Peritoneal Mesothelioma: Treatment Approaches and Factors Affecting Survival
SEVER N., Yildirim S., Gürbüz A. F., Karakaş Kiliç D., Zeynelgil E., Altintaş Y. E., et al.
Journal of Oncological Science
, cilt.11, sa.2, ss.104-111, 2025 (Scopus)
2025
20252. Clinicopathological Features and Survival Outcomes of Colorectal Cancer Patients Under 40 Years: A 20-Years Single-Center Experience
Kaan A., Demircan N. C., ÖZGÜR S. Ş., AKYOL T. B., majıdova n., Kocaaslan E., et al.
Uluslararası Hematoloji-Onkoloji Dergisi
, cilt.35, sa.2, ss.104-111, 2025 (SCI-Expanded, Scopus, TRDizin)
2025
20253. Prognostic Nutritional Index as a Biomarker in Metastatic Hormone-Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization
Hacioglu M. B., Kucukarda A., Gokmen I., Gurbuz A. F., Araz M., Kahvecioglu F. A., et al.
Prostate
, cilt.85, sa.7, ss.693-702, 2025 (SCI-Expanded)
2025
20254. Efficacy of Second-Line Treatments After Atezolizumab and Bevacizumab in Advanced Hepatocellular Carcinoma and Related Prognostic Factors: A Multicenter Study by the Turkish Oncology Group (TOG)
majıdova n., Yaslikaya S., Mildanoğlu M., Coşkun A., Uzundal D. E., Sahin T. K., et al.
Turkish Journal of Gastroenterology
, cilt.36, sa.5, ss.293-301, 2025 (SCI-Expanded)
2025
20255. Evaluation of Pancreatic Atrophy in Patients with Hepatocellular Carcinoma Receiving Sorafenib Treatment
Kaan A., Zengin G., majıdova n., SEVER N., Ergelen R., Köstek O., et al.
Eurasian Journal of Medical Investigation
, cilt.9, sa.1, ss.29-35, 2025 (Hakemli Dergi)
2025
20256. Kas-İnvaziv mesane kanserinde neoadjuvan ve adjuvan kemoterapinin sağkalım üzerine etkinliği: Çok merkezli çalışma
majıdova n., Öztürk A. E., Çolak R., yalıcı ö., İÇLİ M. C., KÖKSAL B., et al.
Turkish Journal of Clinics and Laboratory
, cilt.16, sa.1, ss.123-130, 2025 (Hakemli Dergi)
2025
20257. Prognostic Factors in High Grade Osteosarcoma Patients Who Received Neoadjuvant Therapy and Subsequently Underwent Surgery: Data from the Turkish Oncology Group
SEVER N., ŞİMŞEK F., Onur İ. D., Arvas H., GULIYEV T., Şakalar T., et al.
Journal of Clinical Medicine
, cilt.14, sa.6, 2025 (SCI-Expanded)
2025
20258. Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2− Metastatic Breast Cancer: A Multicenter Comparison of HER2-Low and HER2-Zero Subgroups
Ozcan E., Gokmen I., Akgul F., Kahvecioglu F. A., Celebi A., KÖSTEK O., et al.
Breast Journal
, cilt.2025, sa.1, 2025 (SCI-Expanded)
2025
20259. The Effect of PET/CT SUV max Value on Anti-EGFR Treatment Response in Lung Adenocarcinoma
Ercelep O., Isik S., ERCAN E., KÖSTEK O., Bayoglu V., Celebi A., et al.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
, cilt.35, sa.3, ss.159-165, 2025 (SCI-Expanded, Scopus)
2025
202510. The Effect of Systemic Inflammation and Clinicopathologic Features on Survival in Malignant Pleural Mesothelioma: A Multicenter Analysis
SEVER N., Yıldırım S., Gurbuz A. F., Karakaş Kılıç D., Zeynelgil E., Altintaş Y. E., et al.
Medicina (Lithuania)
, cilt.61, sa.1, 2025 (SCI-Expanded)
2024
202411. Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases
Kahraman S., Karakaya S., Kaplan M. A., SEZGİN GÖKSU S., Ozturk A., Isleyen Z. S., et al.
Scientific Reports
, cilt.14, sa.1, 2024 (SCI-Expanded)
2024
202412. HER2 exon 20 mutant non-small cell lung cancer with complete remission of intracranial metastases with trastuzumab deruxtecan: A case report
Güren A. K., KOCAASLAN E., AĞYOL Y., Majidova N., Sever N., EREL P., et al.
Anti-Cancer Drugs
, cilt.35, sa.8, ss.769-773, 2024 (SCI-Expanded)
2024
202413. Evaluating the Role of Nrf-2/HO-1 Pathway in Glioblastoma Treatment Efficacy: A Co-Culture Study
Güneş Z., Başkent M. F., Arslan S., Atasoy B. M., Köstek O., Şahin A., et al.
CLINICAL AND EXPERIMENTAL HEALTH SCIENCES
, cilt.14, sa.3, ss.760-767, 2024 (ESCI)
2024
202414. Evaluating therapeutic efficacy of extended shelf-life90Y glass microspheres in transarterial radioembolization for colorectal cancer: a quantitative FDG PET/CT analysis
KESİM S., Balaban Genc Z. C., SOYDEMİR E., BALTACIOĞLU F., Kissa T. N., ÖZDEMİR B., et al.
Nuclear Medicine Communications
, cilt.45, sa.4, ss.268-277, 2024 (SCI-Expanded)
2024
202415. The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing
KÖSTEK O., DEMİREL A., Hacıoğlu M. B., TAŞTEKİN D., KARABULUT S., Gündogdu A., et al.
Journal of Chemotherapy
, cilt.36, sa.7, ss.613-621, 2024 (SCI-Expanded, Scopus)
2024
202416. Prognostic Factors Associated with Resected Osteosarcoma: Efficacy of Adjuvant Setting, Real-World Experience
Majidova N., ŞİMŞEK F., Biter S., YASLIKAYA Ş., Seyyar M., DUYGULU M. E., et al.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi
, cilt.34, sa.1, ss.20-27, 2024 (SCI-Expanded, Scopus, TRDizin)
2024
202417. Systemic Inflammation Response Index and Pan-Immune-Inflammation Value: Prognostic Significance in Metastatic Melanoma
Majidova N., Kircali M. F., Güren A. K., Sever N., KOCAASLAN E., AĞYOL Y., et al.
Journal of Oncological Science
, cilt.10, sa.3, ss.144-149, 2024 (Scopus)
2024
202418. Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy
Ilhan Y., Ucar G., Baser M. N., Guzel H. G., Efil S. C., Demir B., et al.
Expert Opinion on Pharmacotherapy
, cilt.25, sa.11, ss.1555-1563, 2024 (SCI-Expanded)
2023
202319. PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score
BAYOĞLU İ. V., Hüseynov J., Topal A., Sever N., Majidova N., Çelebi A., et al.
Journal of Clinical Medicine
, cilt.12, sa.19, 2023 (SCI-Expanded)
2023
202320. Major and minor salivary gland cancers: A multicenter retrospective study
Hacioglu M. B., ERDOĞAN B., Bardakcı M., Algın E., Gulbagcı B., Hacibekiroglu I., et al.
Head and Neck
, cilt.45, sa.7, ss.1643-1653, 2023 (SCI-Expanded)
2023
202321. Prognostic significance of 18F-FDG PET/CT indices in metastatic renal cell cancer and evaluation of revised IMDC risk model by including 18F-FDG PET-CT parameters.
Arikan R., Ozguven S., Telli T. A., Isik S., Demircan N. C., Basoglu T., et al.
Acta radiologica (Stockholm, Sweden : 1987)
, cilt.64, sa.5, ss.2040-2049, 2023 (SCI-Expanded)
2023
202322. Prognostic Significance of Mucinous Histology in Metastatic Colorectal Cancer Patients Treated with Regorafenib
ARIKAN R., Üstün H. S., Demircan N. C., Işik S., Telli T. A., Yaşar A., et al.
Journal of Oncological Science
, cilt.9, sa.2, ss.53-61, 2023 (Scopus)
2022
202223. BRCA 1/BRCA 2 Pathogenic/Likely Pathogenic Variant Patients with Breast, Ovarian, and Other Cancers
Osman K., Ahmet K., Hilmi T., Ilker N., Ercan O., Devrim C., et al.
Balkan Journal of Medical Genetics
, cilt.25, sa.2, ss.5-14, 2022 (SCI-Expanded)
2022
202224. Real-world assessment of quality-of-life in patients with breast cancer treated with adjuvant endocrine therapy
AKIN TELLİ T., ÖZTÜRK M. S., Alan O., Hasanov R., KÖSTEK O., Arikan R., et al.
FUTURE ONCOLOGY
, cilt.18, ss.2425-2439, 2022 (SCI-Expanded)
2022
202225. Predictive value of (18)F-FDG PET/CT indices on extensive residual cancer burden in breast cancer patients treated with neoadjuvant chemotherapy.
Başoğlu T., Özgüven S., Özkan H. Ş., Çınar M., Köstek O., Demircan N. C., et al.
Revista espanola de medicina nuclear e imagen molecular
, cilt.41, sa.3, ss.171-178, 2022 (SCI-Expanded)
2022
202226. Predictive value of 18F-FDG PET/CT indices on extensive residual cancer burden in breast cancer patients treated with neoadjuvant chemotherapy Valor predictivo de los índices 18F-FDG PET/TC sobre la carga tumoral residual en pacientes con cáncer de mama extenso tratadas con quimioterapia neoadyuvante
Başoğlu T., ÖZGÜVEN S., ŞAHİN ÖZKAN H., Çınar M., Köstek O., Can Demircan N., et al.
Revista Espanola de Medicina Nuclear e Imagen Molecular
, cilt.41, ss.171-178, 2022 (SCI-Expanded)
2022
202227. Comparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinoma
Gokyer A., Kucukarda A., Kostek O., Gokmen I., Ozcan E., Sayin S., et al.
TUMORI JOURNAL
, cilt.108, sa.2, ss.141-146, 2022 (SCI-Expanded)
2022
202228. The Relationship between Nutritional Parameters and Thrombosis Risk in Cancer Patients
Sari M., İLHAN Y., SEZGİN GÖKSU S., Kostek O., TATLI A. M., Coskun H. S.
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
, cilt.74, sa.4, ss.1370-1375, 2022 (SCI-Expanded)
2022
202229. Value of FDG PET/CT in Predicting Pathologic Complete Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer
AYHAN M., ABAMOR E., Coban Kokten S., ODABAŞ H., TATAROĞLU ÖZYÜKSELER D., KÖSTEK O., et al.
Eurasian Journal of Medical Investigation
, cilt.6, ss.165-175, 2022 (Hakemli Dergi)
2022
202230. Prognostic Factors for Survival in Transverse Colon Cancers
Kucukarda A., Gokyer A., Sayin S., Gokmen I., Ozcan E., Kostek O., et al.
JOURNAL OF GASTROINTESTINAL CANCER
, cilt.53, sa.1, ss.31-40, 2022 (ESCI)
2022
202231. Varicella-Zoster Virus Infection and Brivudine Therapy: Unexpected Response in Sarcoma Patient
KÖSTEK O., Sari M., BAYOĞLU İ. V.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, cilt.6, sa.2, ss.182-185, 2022 (ESCI)
2022
202232. Impact of Skeletal Muscle Measurements by Chest Computed Tomography on Survival and Postoperative Complications in Patients with Soft Tissue Sarcoma
AKIN TELLİ T., BUĞDAYCI O., Alan O., Sariyar N., Isik S., Arikan R., et al.
Nutrition and Cancer
, cilt.74, sa.7, ss.2499-2507, 2022 (SCI-Expanded)
2022
202233. First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer.
Aktürk Esen S., Ergun Y., Erol C., Arikan R., Er M. M., Atci M. M., et al.
Bosnian journal of basic medical sciences
, cilt.22, ss.818-825, 2022 (SCI-Expanded)
2021
202134. Factors affecting the mortality rate of patients with cancer hospitalized with COVID-19: a single center's experience
Ayhan M., Odabas H., Turan N., Ozyukseler D. T., Kostek O., Alkan G., et al.
JOURNAL OF CHEMOTHERAPY
, cilt.33, sa.7, ss.499-508, 2021 (SCI-Expanded)
2021
202135. Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?
Erdogan B., Kostek O., Bekir Hacioglu M., Gokyer A., Kucukarda A., Ozcan E., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.26, sa.5, ss.2196-2201, 2021 (SCI-Expanded)
2021
202136. The association between post-progression survival and clinical characteristics of patients with metastatic colon cancer: A single center experience.
Engin Ozekin M., Gokyer A., Kucukarda A., Kostek O., Issever K., Erdogan B.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.26, sa.5, ss.1887-1892, 2021 (SCI-Expanded)
2021
202137. Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.
Tural D., Olmez O. F., Sumbul A. T., ARTAÇ M., Ozhan N., Akar E., et al.
European urology focus
, cilt.7, sa.5, ss.1061-1066, 2021 (SCI-Expanded)
2021
202138. Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab.
Tural D., Olmez O. F., Sumbul A. T., Ozhan N., ÇAKAR B., Kostek O., et al.
International journal of clinical oncology
, cilt.26, sa.8, ss.1506-1513, 2021 (SCI-Expanded)
2021
202139. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience
Bahceci A., PAYDAŞ S., Ak N., Ferhatoglu F., Saip P. M., SEYDAOĞLU G., et al.
CANCER INVESTIGATION
, cilt.39, sa.6-7, ss.473-481, 2021 (SCI-Expanded)
2021
202140. Real-life data on first-line Sunitinib and Pazopanib therapy in metastatic renal cell carcinoma patients: a single center experience.
Topal A., Sayın S., Gokyer A., Kucukarda A., Kostek O., Bekir Hacıoglu M., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.26, sa.4, ss.1628-1634, 2021 (SCI-Expanded)
2021
202141. Does the efficacy of regorafenib differ in chemotherapy refractory metastatic colorectal cancer patients who had mucinous pathology compared to those who had non-mucinous pathology?
Ayhan M., Turan N., Kostek O., Tufan G., Ozyukseler D. T., Odabas H., et al.
CURRENT PROBLEMS IN CANCER
, cilt.45, sa.3, 2021 (SCI-Expanded)
2021
202142. Skeletal muscle loss during anti-epidermal growth factor receptor therapy is an independent prognostic factor on non-small cell lung cancer patients survival.
Kucukarda A., Gokyer A., Gokmen I., Bekir Hacioglu M., Kostek O., Kurt N., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.26, sa.3, ss.853-860, 2021 (SCI-Expanded)
2021
202143. The relation between tissue galectin-3 level and platinum resistance in neoadjuvant bladder cancer treatment.
Gokyer A., Kucukarda A., Kostek O., Sayin S., Can N., Hacıoglu B., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.26, sa.3, ss.1034-1039, 2021 (SCI-Expanded)
2021
202144. Is lymph node dissection necessary for staging while undergoing nephrectomy in patients with renal cell carcinoma?
Demir T., Aliyev A., BEŞİROĞLU M., Araz M., Kostek O., Sakin A., et al.
CURRENT PROBLEMS IN CANCER
, cilt.45, sa.1, 2021 (SCI-Expanded)
2021
202145. Perioperative myocardial damage and the incidence of type 2 myocardial infarction in patients with intermediate and high cardiovascular risk
Keskinler M. V., Kostek O., Erok B., Telci O., Danacioglu O., OĞUZ A.
ANATOLIAN JOURNAL OF CARDIOLOGY
, cilt.25, sa.2, ss.89-95, 2021 (SCI-Expanded)
2021
202146. Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.
Tural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., et al.
JOURNAL OF CLINICAL ONCOLOGY
, cilt.39, sa.6, 2021 (SCI-Expanded)
2021
202147. Comparative assessment of three different second-line regimens in chemotherapy resistant / refractory small-cell lung cancer.
Hacibekiroglu I., Ozkul O., Cakir E., Kostek O., Karatas F., Esenkaya A., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.26, sa.1, ss.79-86, 2021 (SCI-Expanded)
2020
202048. Comparing Late-line Treatment Sequence of Regorafenib and Reduced-intensity FOLFOXIRI for Refractory Metastatic Colorectal Cancer
Kostek O.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
, cilt.43, sa.12, ss.905, 2020 (SCI-Expanded)
2020
202049. Introduction of a novel quantitative scoring system for acanthosis nigricans and its validation in a pilot study
Karadag A. S., Uzuncakmak T. K., Ozlu E., Takir M., Karadag R., Kostek O., et al.
DERMATOLOGIC THERAPY
, cilt.33, sa.6, 2020 (SCI-Expanded)
2020
202050. Contrast nephropathy in cancer patients receiving anti-VEGF therapy: a prospective study
Gokyer A., Kucukarda A., Kostek O., Hacioglu M. B., UZUNOĞLU S., Kula O., et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
, cilt.25, sa.10, ss.1757-1762, 2020 (SCI-Expanded)
2020
202051. Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?
Ucar G., Acikgoz Y., Ergun Y., Bal O., Yilmaz M., Karakaya S., et al.
CUREUS
, cilt.12, sa.9, 2020 (ESCI)
2020
202052. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey.
Hacioglu M. B., Kostek O., Karabulut S., Tastekin D., SEZGİN GÖKSU S., Alandag C., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.25, sa.4, ss.1897-1903, 2020 (SCI-Expanded)
2020
202053. The relationship between FDG PET/CT-defined metabolic parameters and the histopathological subtype of oesophageal carcinomas
Korkmaz U., Hacioglu M. B., Kostek O., SÜT N., Kodaz H., ERDOĞAN B., et al.
POLISH JOURNAL OF RADIOLOGY
, cilt.85, 2020 (ESCI)
2020
202054. Sarcopenia and Inflammation with Immunotherapy
Kostek O., Demir T.
ONCOLOGIST
, cilt.25, sa.5, 2020 (SCI-Expanded)
2020
202055. Is the prognostic nutritional index a prognostic and predictive factor in metastatic non-small cell lung cancer patients treated with first-line chemotherapy?
Bozkaya Y., Kostek O., Sakin A., Ozyukseler D. T., Sakalar T., Cil I.
SUPPORTIVE CARE IN CANCER
, cilt.28, sa.5, ss.2273-2282, 2020 (SCI-Expanded)
2020
202056. Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience.
Tural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., et al.
Journal of oncological sciences , cilt.38, sa.6_suppl, ss.1-5, 2020 (SCI-Expanded)
2020
202057. Does celiac disease impair coronary microvascular circulation: Coronary flow velocity reserve of patients with celiac disease
Caliskan Z., TELCİ ÇAKLILI Ö., Kahraman R., Ozcan F. B., Sayar S., Kostek O., et al.
ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES
, cilt.37, sa.1, ss.34-40, 2020 (SCI-Expanded)
2019
201958. The albumin-bilirubin (ALBI) grade as a significant prognostic factor in colorectal cancer patients with liver metastases
DEMİRCAN N. C., KÖSTEK O., GÖKYER A., KÜÇÜKARDA A., HACIOĞLU M. B., ERDOĞAN B., et al.
Journal of Surgery and Medicine , 2019 (Hakemli Dergi)
2019
201959. Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib
Gokyer A., Kucukarda A., Kostek O., Hacioglu M. B., Sunal B. S., Demircan N. C., et al.
CLINICAL & TRANSLATIONAL ONCOLOGY
, cilt.21, sa.11, ss.1518-1523, 2019 (SCI-Expanded)
2019
201960. Skeletal muscle loss during anti-EGFR combined chemotherapy regimens predicts poor prognosis in patients with RAS wild metastatic colorectal cancer
Kostek O., Demircan N. C., Gokyer A., Kucukarda A., Sunal B. S., Hacioglu M. B., et al.
CLINICAL & TRANSLATIONAL ONCOLOGY
, cilt.21, sa.11, ss.1510-1517, 2019 (SCI-Expanded)
2019
201961. Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102.
Bekir Hacioglu M., Kostek O., Kurt N., Kucukarda A., Gokyer A., Ustabasioglu F. E., et al.
Journal of B.U.ON. : official journal of the Balkan Union of Oncology
, cilt.24, sa.5, ss.2198-2204, 2019 (SCI-Expanded)
2019
201962. Pür Seminom Vakalarının Klinik Özellikleri ve Tedavi Sonrası İzlemleri: Tek Merkez Deneyimi
GÖKYER A., KÜÇÜKARDA A., KÖSTEK O.
Namık Kemal Tıp Dergisi , cilt.7, sa.2, ss.128-132, 2019 (Hakemli Dergi)
2019
201963. Clinical characteristics and overdose risk factors of patients hospitalized due to warfarin overdose
ORAL A., BAŞÇI S., KÖSTEK O., UZUNLULU M.
Demiroğlu Bilim Üniversitesi Florence Nightingale Tıp Dergisi , cilt.5, sa.2, ss.63-71, 2019 (Hakemli Dergi)
2019
201964. Effect of low-dose acitretin treatment on pituitary hormones in psoriasis vulgaris: A retrospective study
Karadag A. S., Ozlu E., Kostek O., Bilgili S. G., Balaharoglu R., Ertugrul D. T.
INDIAN JOURNAL OF DERMATOLOGY VENEREOLOGY & LEPROLOGY
, cilt.85, sa.3, ss.300-304, 2019 (SCI-Expanded)
2019
201965. Is the Charlson Comorbidity Index a Prognostic Indicator for Toxicity and Mortality in Elderly Patients with Locally Advanced Rectal Cancer?
Kostek O., Bozkaya Y., Hacioglu M. B., Ozdemir N. Y., Yilmaz E., Demircan N. C., et al.
ARCHIVES OF IRANIAN MEDICINE
, cilt.22, sa.5, ss.236-241, 2019 (SCI-Expanded)
2019
201966. Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer
Kostek O., Yilmaz E., Hacioglu M. B., Demircan N. C., Gokyer A., UZUNOĞLU S., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
, cilt.83, sa.4, ss.735-742, 2019 (SCI-Expanded)
2019
201967. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients
Bozkaya Y., Erdem G. U., Demirci N. S., Yazic O., Ozdemir N. Y., Kostek O., et al.
CURRENT MEDICAL RESEARCH AND OPINION
, cilt.35, sa.2, ss.275-282, 2019 (SCI-Expanded)
2019
201968. Effect of somatostatin analogs on prostate volume Somatostatin analoglarinin prostat volümü üzerine etkisi
Kostek O., Hacioglu M. B.
Medeniyet Medical Journal
, cilt.34, sa.2, ss.176-181, 2019 (Scopus)
2019
201969. Assessment of Duodenal Diverticula: Computed Tomography Findings
Yilmaz E., Kostek O., Hereklioglu S., Goktas M., TUNÇBİLEK N.
CURRENT MEDICAL IMAGING
, cilt.15, sa.10, ss.948-955, 2019 (SCI-Expanded)
2019
201970. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?
Kostek O., Hacioglu M. B., Sakin A., Demir T., Sari M., Ozkul O., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
, cilt.83, sa.1, ss.115-122, 2019 (SCI-Expanded)
2019
201971. Lipid profile, atherogenic indices, and their relationship with epicardial fat thickness and carotid intima-media thickness in celiac disease
Caliskan Z., Demircioglu K., Sayar S., Kahraman R., TELCİ ÇAKLILI Ö., Ozcan F. B., et al.
NORTHERN CLINICS OF ISTANBUL
, cilt.6, sa.3, ss.242-247, 2019 (ESCI)
2019
201972. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naive breast cancer: real-life practice outcomes
Esin E., Oksuzoglu B., Bilici A., Cicin I., Kostek O., Kaplan M. A., et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
, cilt.83, sa.1, ss.131-143, 2019 (SCI-Expanded)
2019
201973. The impact of prognostic nutritional index on coronary flow reserve in patients with inflammatory bowel disease İnflamatuvar bağırsak hastalarında prognostik nütrisyonel indeksin koroner akım rezervi üzerine etkisi
Caliskan Z., Tatlisu M. A., Kahraman R., Gokturk S., Sayar S., Kostek O., et al.
Medeniyet Medical Journal
, cilt.34, sa.3, ss.271-277, 2019 (Scopus)
2018
201874. Investigation of prevalence of insulin resistance and metabolic syndrome in patients with gastric and colon carcinoma
Çelik M., AKYER E., YORULMAZ E., ÇİFTÇİ H., ÇAKICI V., KÖSTEK O.
Eurasian Journal of Medical Investigation , cilt.2, sa.3, ss.168-171, 2018 (Hakemli Dergi)
2018
201875. A retrospective study on potential drug interactions: A single center experience
Korucu F. C., Senyigit E., KÖSTEK O., Demircan N. C., Erdogan B., Uzunoglu S., et al.
Journal of Oncological Sciences , cilt.4, sa.2, ss.80-84, 2018 (Hakemli Dergi)
2018
201876. Value of MRI apparent diffusion coefficient for assessment of response to sorafenib in hepatocellular carcinoma
Kostek O., Yilmaz E., Hacioglu M. B., ERDOĞAN B., Kodaz H., Bekmez E. T., et al.
JOURNAL OF BUON
, cilt.23, sa.4, ss.979-984, 2018 (SCI-Expanded)
2018
201877. Enzalutamide in Prostate Cancer, A Review on Enzalutamide and cancer
ERDOĞAN B., KÖSTEK O., HACIOĞLU M. B.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, cilt.2, sa.3, ss.121-129, 2018 (Hakemli Dergi)
2018
201878. BRAF V600 Mutation Profile of Metastatic Melanoma in the Thrace Region of Turkey
CAN N., TAŞTEKİN E., Deniz Yalta T., SÜT N., KORKMAZ S., USTA U., et al.
TURKISH JOURNAL OF PATHOLOGY
, cilt.34, sa.2, ss.134-142, 2018 (ESCI)
2018
201879. Clinical predictive factors associated with pathologic complete response in locally advanced rectal cancer
Bozkaya Y., Özdemir N. Y., Erdem G. U., Güner E. K., Ürün Y., Demirci N. S., et al.
Journal of Oncological Sciences , cilt.4, sa.1, ss.5-10, 2018 (Hakemli Dergi)
2018
201880. Endocan: a novel predictor of endothelial dysfunction in obstructive sleep apnea syndrome
Kanbay A., Ceylan E., Koseoglu H. I., ÇALIŞKAN M., Takir M., Tulu S., et al.
CLINICAL RESPIRATORY JOURNAL
, cilt.12, sa.1, ss.84-90, 2018 (SCI-Expanded)
2018
201881. Assessment of cardiovascular findings in FMF related amyloid patients Ailevi akdeniz ateşine ikincil gelişen amiloidozda kardiyovasküler bulguların değerlendirilmesi
Köstek O., Takir M., Çalişkan M., Oğuz A.
Medeniyet Medical Journal
, cilt.33, sa.3, ss.149-157, 2018 (Scopus)
2018
201882. Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy?
Bozkaya Y., Ozdemir N. Y., Sezer S., Kostek O., Demirci N. S., Yazici O., et al.
CANCER BIOMARKERS
, cilt.22, sa.1, ss.143-149, 2018 (SCI-Expanded)
2017
201783. Effects of Low Intensity Exercise Against Apoptosis and Oxidative Stress in Streptozotocin-induced Diabetic Rat Heart
Kanter M., Aksu F., Takir M., Kostek O., Kanter B., Oymagil A.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
, cilt.125, sa.9, ss.583-591, 2017 (SCI-Expanded)
2017
201784. Cardiac invasion of HCC: Clinical image
KÖSTEK O., karakaya tosun i., Tecimen H., Kodal N. S.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, cilt.1, sa.4, ss.243, 2017 (Hakemli Dergi)
2017
201785. A Rare Cause of Acute Kidney Injury: Renal ArterialThrombosis in a Small Cell Lung Cancer Patient
KÖSTEK O., HACIOĞLU M. B., ORMAN S., ÇETİN C., KODAL N. S., ERDOĞAN B., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, cilt.1, sa.1, ss.41-43, 2017 (Hakemli Dergi)
2017
201786. Assessment of prognostic factors in epithelial ovarian cancer
ÖNAL Y., KÖSTEK O., HACIOĞLU M. B., ERDOĞAN B., KODAZ H., TÜRKMEN BEKMEZ E., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, cilt.1, sa.2, ss.61-68, 2017 (Hakemli Dergi)
2017
201787. Combination of Docetaxel and Gemcitabine Ineffective in Metastatic Eccrine Porocarcinoma: A Case Report
KODAZ H., HACIOĞLU M. B., KÖSTEK O., ERDOĞAN B., TAŞTEKİN E., KODAZ ELPEN Ç., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, cilt.1, sa.1, ss.38-40, 2017 (Hakemli Dergi)
2017
201788. The effect of CPAP therapy on insulin-like growth factor and cognitive functions in obstructive sleep apnea patients
Kanbay A., Demir N. C., TUTAR N., Kostek O., Simsek Z. O., Buyukoglan H., et al.
CLINICAL RESPIRATORY JOURNAL
, cilt.11, sa.4, ss.506-513, 2017 (SCI-Expanded)
2017
201789. Metastasis of Transitional Cell Carcinoma of the Bladder to the Orbit: A Case Report
GENÇ A. C., HACIOĞLU M. B., KÖSTEK O., HACIBEKİROĞLU İ.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, cilt.1, sa.1, ss.47-48, 2017 (Hakemli Dergi)
2017
201790. Frequency of RAS Mutations (KRAS, NRAS, HRAS) in Human Solid Cancer
KODAZ H., KÖSTEK O., HACIOĞLU M. B., ERDOĞAN B., KODAZ ELPEN Ç., HACIBEKİROĞLU İ., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY
, cilt.1, sa.1, ss.1-7, 2017 (Hakemli Dergi)
2017
201791. Morning blood pressure surge is associated with carotid intima-media thickness in prehypertensive patients
Alpaydin S., Turan Y., ÇALIŞKAN M., Caliskan Z., Aksu F., ÖZYILDIRIM S., et al.
BLOOD PRESSURE MONITORING
, cilt.22, sa.3, ss.131-136, 2017 (SCI-Expanded)
2017
201792. Chemerin as a marker of subclinical cardiac involvement in psoriatic patients
Aksu F., ÇALIŞKAN M., Keles N., Toprak A. E., Uzuncakmak T. K., Kostek O., et al.
CARDIOLOGY JOURNAL
, cilt.24, sa.3, ss.276-283, 2017 (SCI-Expanded)
2017
201793. Targeted therapy with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer even with brain metastasis
Hacioglu B. M., Kostek O., ERDOĞAN B., UZUNOĞLU S., ÇİÇİN İ.
JOURNAL OF BUON
, cilt.22, sa.3, ss.586-591, 2017 (SCI-Expanded)
2017
201794. Skin findings in autoimmune and nonautoimmune thyroid disease with respect to thyroid functional status and healthy controls
Takir M., Ozlu E., Kostek O., Turkoglu Z., MUTLU H. H., Uzuncakmak T. K., et al.
TURKISH JOURNAL OF MEDICAL SCIENCES
, cilt.47, sa.3, ss.764-770, 2017 (SCI-Expanded)
2017
201795. Clinical features of the patient with multiple primary tumors: Single center experience
Gokyer A., Kostek O., Hacioglu M. B., ERDOĞAN B., Kodaz H., Turkmen E., et al.
NORTHERN CLINICS OF ISTANBUL
, cilt.4, sa.1, ss.43-51, 2017 (ESCI)
2017
201796. K-RAS and N-RAS mutations in testicular germ cell tumors
Hacioglu B. M., Kodaz H., ERDOĞAN B., Cinkaya A., TAŞTEKİN E., Hacibekiroglu I., et al.
BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES
, cilt.17, sa.2, ss.159-163, 2017 (SCI-Expanded)
2017
201797. Effects of the Clinical and Biochemical Features of Patients with Treatment-Resistant Primary Nephrotic Syndrome on Renal Survival
Bilgin S., Ozkok A., Kostek O., Basci S., ÖZKANLI S. Ş., ODABAŞ A. R.
TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL
, cilt.26, sa.1, ss.79-85, 2017 (ESCI)
2017
201798. Bone Mineral Density and Osteoporosis in Hyponatremic Versus Normonatremic Patients: A Retrospective 12-Month Analysis
Takir M., Bakan A., Tahra S. T., Kostek O., Erek A., Duran I., et al.
TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL
, cilt.26, sa.1, ss.29-34, 2017 (ESCI)
2016
201699. The Influence of On-pump Versus Off-pump Surgery on Short- and Medium-term Postoperative Coronary Flow Reserve After Coronary Artery Bypass Grafting
Ozulku M., Caliskan M., Saba T., Aksu F., Ciftci O., Gullu H., et al.
HEART LUNG AND CIRCULATION
, cilt.25, sa.12, ss.1232-1239, 2016 (SCI-Expanded)
2016
2016100. Is activation in inflammatory bowel diseases associated with further impairment of coronary microcirculation?
Caliskan Z., Keles N., Gokturk H. S., Ozdil K., Aksu F., Ozturk O., et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY
, cilt.223, ss.176-181, 2016 (SCI-Expanded)
2016
2016101. Cystatin-C and TGF-beta levels in patients with diabetic nephropathy
Takir M., Unal A. D., Kostek O., Bayraktar N., Demirag N. G.
NEFROLOGIA
, cilt.36, sa.6, ss.653-659, 2016 (SCI-Expanded)
2016
2016102. Coronary Flow Velocity Reserve in Burn Injury: A Prospective Clinical Cohort Study
ÇALIŞKAN M., Turk E., Karagulle E., Ciftci O., Oguz H., Kostek O., et al.
JOURNAL OF BURN CARE & RESEARCH
, cilt.37, sa.5, 2016 (SCI-Expanded)
2016
2016103. Is the presence of AA amyloidosis associated with impaired coronary flow reserve?
Bulut M., Keles N., Caliskan Z., Kostek O., Aksu F., Ozdil K., et al.
ATHEROSCLEROSIS
, cilt.251, ss.389-395, 2016 (SCI-Expanded)
2016
2016104. Durable response with medroxiprogesterone acetate in metastatic renal cell carcinoma: Case report
Hacioglu B. M., KÖSTEK O., ERDOĞAN B., Hilmi K., HACIBEKİROĞLU İ., Turkmen E., et al.
Journal of Oncological Sciences , cilt.2, sa.2-3, ss.69-70, 2016 (Hakemli Dergi)
2016
2016105. Relationship Between Papillary Thyroid Cancer And Hashimoto’s Disease
Erdoğmuş S., Mümtaz T., KÖSTEK O., Şenol S., Mutlu H. H.
Medeniyet medical journal
, cilt.31, sa.1, ss.186-191, 2016 (Scopus)
2016
2016106. Is Low Serum Klotho Level Associated with Alterations in Coronary Flow Reserve?
Keles N., ÇALIŞKAN M., Dogan B., Aksu F., Bulur S., Keles N. N., et al.
ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES
, cilt.33, sa.6, ss.881-888, 2016 (SCI-Expanded)
2016
2016107. Chronic rhinosinusitis, endothelial dysfunction, and atherosclerosis
ELÇİOĞLU Ö. C., Afsar B., Bakan A., Takir M., Ozkok A., Oral A., et al.
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
, cilt.30, sa.3, 2016 (SCI-Expanded)
2016
2016108. The relation of presenting symptoms with staging, grading, and postoperative 3-year mortality in patients with stage I-III non-metastatic colon cancer
Bedir O., Kiziltas S., Kostek O., ÖZKANLI S. Ş.
TURKISH JOURNAL OF GASTROENTEROLOGY
, cilt.27, sa.3, ss.239-245, 2016 (SCI-Expanded)
2016
2016109. The effects of quercetin on liver regeneration after liver resection in rats
Kanter M., TUNCER İ., Erboga M., Atanassova P., Takir M., Kostek O.
FOLIA MORPHOLOGICA
, cilt.75, sa.2, ss.179-187, 2016 (SCI-Expanded)
2016
2016110. Echocardiographic Epicardial Fat Thickness Measurement and Cardiovascular Risk Assessment in Patients with Systemic Lupus Erythematosus
Nurşen K., Aksu F., Açıksarı G., Demircioğlu K., Yılmaz Y., KÖSTEK O., et al.
Medeniyet medical journal
, cilt.31, sa.2, ss.115-121, 2016 (Scopus)
2016
2016111. Sistemik AA Amiloidozlu Hastalarda Epikardiyal Yağ DokusuKalınlığı, Benek Takibi Ekokardiyografik Parametreleri veYüksek Duyarlıklı C Reaktif Protein Düzeyleri
keleş n., ÇALIŞKAN M., elçioğlu ö. c., akçakoyun m., bakan a., KÖSTEK O., et al.
MN Kardiyoloji , cilt.23, sa.1, ss.19-27, 2016 (Hakemli Dergi)
2016
2016112. C-reactive protein but not hepcidin, NGAL and transferrin determines the ESA resistance in hemodialysis patients
Yilmaz I., Ozkok A., Kostek O., Kolukisa A., Duran I., ODABAŞ A. R., et al.
RENAL FAILURE
, cilt.38, sa.1, ss.89-95, 2016 (SCI-Expanded)
2016
2016113. Is serum Klotho protective against atherosclerosis in patients with type 1 diabetes mellitus?
Keles N., Dogan B., Kalcik M., ÇALIŞKAN M., Keles N. N., Aksu F., et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS
, cilt.30, sa.1, ss.126-132, 2016 (SCI-Expanded)
2016
2016114. Association Between Elevated Serum Uric Acid and Vitamin D Insufficiency Among the Middle-Aged and Elderly Population
Takir M., Solak Y., Erek A., Kostek O., Oral A., ELÇİOĞLU Ö. C., et al.
TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL
, cilt.25, sa.2, ss.182-186, 2016 (ESCI)
2016
2016115. Is triglyceride/HDL ratio a reliable screening test for assessment of atherosclerotic risk in patients with chronic inflammatory disease?
Keles N., Aksu F., Aciksari G., Yilmaz Y., Demircioglu K., Kostek O., et al.
NORTHERN CLINICS OF ISTANBUL
, cilt.3, sa.1, ss.39-45, 2016 (ESCI)
2016
2016116. Protective Effects of Curcumin on Intestinal Damage in Cholestatic Rats
Kanter M., Takir M., MUTLU H. H., Kanter B., Kostek O., Toprak A. E.
JOURNAL OF INVESTIGATIVE SURGERY
, cilt.29, sa.3, ss.128-136, 2016 (SCI-Expanded)
2016
2016117. An unusual case of peritonitis after vaginal leak in a patient on peritoneal dialysis
Bakan A., Oral A., Kostek O., Ecder S. A., ODABAŞ A. R.
NEFROLOGIA
, cilt.36, sa.1, ss.85-86, 2016 (SCI-Expanded)
2015
2015118. Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia
Takir M., Kostek O., Ozkok A., ELÇİOĞLU Ö. C., Bakan A., Erek A., et al.
JOURNAL OF INVESTIGATIVE MEDICINE
, cilt.63, sa.8, ss.924-929, 2015 (SCI-Expanded)
2015
2015119. Low Serum Level of Klotho Is an Early Predictor of Atherosclerosis
Keles N., ÇALIŞKAN M., Dogan B., Keles N. N., Kalcik M., Aksu F., et al.
TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE
, cilt.237, sa.1, ss.17-23, 2015 (SCI-Expanded)
2015
2015120. Renalase: Another puzzle piece between hypertension and simple renal cysts?
ELÇİOĞLU Ö. C., Afsar B., Takir M., Toprak A. E., Bakan A., Bakan S., et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY
, cilt.47, sa.7, ss.1181-1186, 2015 (SCI-Expanded)
2015
2015121. Association between asthma self-management knowledge and asthma control in the elderly
Ozturk A. B., Pur L. O., Kostek O., Keskin H.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
, cilt.114, sa.6, ss.480-484, 2015 (SCI-Expanded)
2015
2015122. Varfarin tedavisi alan hastalarda koagülasyon testlerinin terapötik aralıkta olma oranı
Erdemoğlu E., Uzunlulu M., Oğuz A., KÖSTEK O., Telci Ç. Ö.
Medeniyet medical journal
, cilt.30, sa.3, ss.105-109, 2015 (Scopus)
2015
2015123. The effects of urgent percutaneous coronary intervention on right ventricular systolic functions in non-ST-elevation acute coronary syndromes
Keles N., Kalcik M., ÇALIŞKAN M., Cakir H., Aung S. M., Kostek O., et al.
INTERVENTIONAL MEDICINE AND APPLIED SCIENCE
, cilt.7, sa.2, ss.69-77, 2015 (ESCI)
2015
2015124. Hyperuricemia is associated with progression of IgA nephropathy
Bakan A., Oral A., ELÇİOĞLU Ö. C., Takir M., Kostek O., Ozkok A., et al.
INTERNATIONAL UROLOGY AND NEPHROLOGY
, cilt.47, sa.4, ss.673-678, 2015 (SCI-Expanded)
2015
2015125. Prognosis of patients in a medical intensive care unit
Unal A. U., Kostek O., Takir M., TELCİ ÇAKLILI Ö., UZUNLULU M., OĞUZ A.
NORTHERN CLINICS OF ISTANBUL
, cilt.2, sa.3, ss.189-195, 2015 (ESCI)
2015
2015126. Retrobulbar blood flow and carotid intima-media thickness alteration may relate to subclinic atherosclerosis in patients with chronic inflammatory diseases
Keles N., ÇALIŞKAN M., Aksu F. U., Keles N. N., Karagoz V., Tekin A. S., et al.
RENAL FAILURE
, cilt.37, sa.7, ss.1164-1170, 2015 (SCI-Expanded)
2015
2015127. The effect of sociodemographic and clinical features on mortality in patients with diagnosis of aspiration pneumonia
Ozer M. N., UZUNLULU M., OĞUZ A., Kostek O., Akyer E., Takir M.
NORTHERN CLINICS OF ISTANBUL
, cilt.2, sa.1, ss.41-47, 2015 (ESCI)
2015
2015128. Previous gestational diabetes history is associated with impaired coronary flow reserve
ÇALIŞKAN M., Turan Y., Caliskan Z., Gullu H., Ciftci F. C., Avci E., et al.
ANNALS OF MEDICINE
, cilt.47, sa.7, ss.615-623, 2015 (SCI-Expanded)
2014
2014129. Endocan: A New Molecule Playing a Role in the Development of Hypertension and Chronic Kidney Disease?
Afsar B., Takir M., Kostek O., Covic A., Kanbay M.
JOURNAL OF CLINICAL HYPERTENSION
, cilt.16, sa.12, ss.914-916, 2014 (SCI-Expanded)
2014
2014130. Zenker’s Diverticulum: Clinical Image
ORAL A., KÖSTEK O., TUNCER İ.
JSM Clinical Case Reports , cilt.2, sa.5, ss.1056, 2014 (Hakemli Dergi)
2014
2014131. Emphysematous pyelonephritis as a cause of diabetic ketoacidosis
KÖSTEK O., TAKIR M., YILMAZ Y., ORAL A.
JSM Clinical Case Reports , cilt.2, sa.6, ss.1065, 2014 (Hakemli Dergi)
2014
2014132. A Potential Treatment of Non-Alcoholic Fatty Liver Disease with SIRT1 Activators
ÇOLAK Y., Yesil A., MUTLU H. H., Caklili O. T., Ulasoglu C., ŞENATEŞ E., et al.
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES
, cilt.23, sa.3, ss.311-319, 2014 (SCI-Expanded)
2014
2014133. Increased morning blood pressure surge and coronary microvascular dysfunction in patient with early stage hypertension
ÇALIŞKAN M., Caliskan Z., Gullu H., Keles N., Bulur S., Turan Y., et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION
, cilt.8, sa.9, ss.652-659, 2014 (SCI-Expanded)
2014
2014134. Functioning beta cells in type 1 diabetes may not be as low as it is presumed
Tamer G., Dogan B., Ocakoglu I., Kostek O., Kartal I., Sagun G., et al.
DIABETOLOGIA
, cilt.57, 2014 (SCI-Expanded)
2014
2014135. Leptin Parameters are Associated with Inflammation and Both Anthropometric and Serum Markers of Protein-Energy Wasting in Hemodialysis Patients
Ozkok A., Isbilen B., Erdemoglu E., Ozberk O. M., TELCİ ÇAKLILI Ö., Kostek O., et al.
TURKISH NEPHROLOGY DIALYSIS AND TRANSPLANTATION JOURNAL
, cilt.23, sa.2, ss.85-90, 2014 (ESCI)
2013
2013136. FREQUENCY OF METABOLIC SYNDROME AND NON ALCOHOLIC FATTY LIVER IN BEHCET'S DISEASE
Ulasoglu C., MESCİ B., Karagoz E., Karagoz V., Akin Y., Ozturk H., et al.
NOBEL MEDICUS
, cilt.9, sa.3, ss.35-42, 2013 (SCI-Expanded)
2013
2013137. A rare complication of a rare disease: Amyloidosis in situs inversus
Ozkok A., Keskinler M. V., Eken E., KÖSTEK O., Caklili O., Oral A., et al.
Open Journal of Internal Medicine , cilt.3, sa.02, ss.55-57, 2013 (Hakemli Dergi)
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler
2024
20241. HIGH BLOOD PRESSURE THERAPY ADHERENCE AND QUALITY OF LIFE IN CANCER PATIENTS WITH HYPERTENSION
YILMAZ F. N., TEZCAN S., KÖSTEK O.
52nd ESCP Symposium on Clinical Pharmacy. Implementing and scaling sustainable clinical pharmacy practice, Krakow, Polonya, 21 - 23 Ekim 2024, (Özet Bildiri)
2023
20232. Alkalen fosfataz yüksekliği ile prezente olan primeri bilinmeyen metastatik adenokarsinom: olgu sunumu
KAVLAK S. Ş., DEMİRTAŞ D., SEVER N., TOPTAŞ T., KÖSTEK O., TAZEGÜL G.
1. Dahiliye Uzmanları Kış Sempozyumu, BAFRA/İSKELE, Kıbrıs (Kktc), 1 - 03 Aralık 2023, (Özet Bildiri)
2019
20193. Ribociclib for the treatment of hormone receptor-positive refractory advanced breast cancer: Managed access programme in Turkey
Demirci U., Gokmen E., Eralp Y., Gunduz S., Goksu S. S., KORKMAZ T., et al.
42nd Annual San Antonio Breast Cancer Symposium, San-Antonio, Kuzey Mariana Adaları, 9 - 14 Aralık 2019, cilt.80, (Özet Bildiri)
2019
20194. THE ASSOCIATION BETWEEN POST-PROGRESSION SURVIVAL AND CLINICAL CHARACTERISTICS OF THE PATIENTS WITH METASTATIC COLORECTAL CANCER
ÖZEKİN M. E., KÖSTEK O., ERDOĞAN B.
9. INTERNATIONAL GASTROINTESTINAL CANCER CONFERENCE, 6 - 08 Aralık 2019, (Özet Bildiri)
2019
20195. MALİGN MELANOM-HEDEFE YÖNELİK TEDAVİDE TARTIŞMALI KONULAR- 4
KÖSTEK O.
3. MUĞLA MULTİDİSİPLİNER ONKOLOJİK ARAŞTIRMALAR KONGRESİ (AMORE 2019), Muğla, Türkiye, 18 - 20 Ekim 2019, ss.58-62, (Tam Metin Bildiri)
2019
20196. PAZOPANİBİN TEDAVİ ETKİNLİĞİ DEĞERLENDİRMEDE SİSTEMİK İNFLAMASYON BELİRTEÇLERİ
KÖSTEK O., HACIOĞLU M. B.
KONYA MULTİDİSİPLİNER ONKOLOJİ SEMPOZYUMU, Konya, Türkiye, 31 Ağustos 2019, (Özet Bildiri)
2019
20197. Real life data from Turkey regarding the impact of first-line sunitinib and pazopanib in metastatic renal cell cancer.
IŞIK U., KÖSTEK O., DEMİRAY A. G., DİRİCAN A., ŞİMŞEK M., BÜYÜKŞİMŞEK M., et al.
ASCO 2019, Chicago, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2019, cilt.37, ss.16075, (Tam Metin Bildiri)
2019
20198. Renal Hücreli Karsinoma Hastalarında Nefrektomi Esnasında Lenf Nodu DiseksiyonuGerekli mi?
DEMİR T., ARAZ M., KÖSTEK O., SAKİN A., SHBAİR A. T., ALİYEV A., et al.
23. ULUSAL KANSER KONGRESİ, Antalya, Türkiye, 17 - 21 Nisan 2019, (Özet Bildiri)
2019
20199. Geriatrik (≥75 Yaş), Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Hastalarında 1. Basamak Anti- Androjen Tedavi Sonuçları- Gerçek Yaşam Verisi
ALKAN A., Güç Z. G., GÜRBÜZ M., Özgün G., DEĞİRMENCİOĞLU S., Doğan M., et al.
23. Ulusal Kanser Kongresi, Türkiye, 17 - 21 Nisan 2019, (Özet Bildiri)
2019
201910. Kastrasyon Dirençli Metastatik Prostat Kanseri (Kdmpk) Olan Geriatrik (≥75 Yaş) Hastalarda 1. Basamak Dosetaksel Tedavi Sonuçlari- Gerçek Yaşam Verisi
ALKAN A., Güç Z. G., GÜRBÜZ M., Özgün G., DEĞİRMENCİOĞLU S., Doğan M., et al.
23. Ulusal Kanser Kongresi, Türkiye, 17 - 21 Nisan 2019, (Özet Bildiri)
2019
201911. OPERE ERKEN EVRE KÜÇÜK HÜCRELİ DIŞI AKCİĞERKANSERLERİNDE LOKAL/BÖLGESEL YİNELEMEPATERNLERİ
ÖZLER T., SAYNAK M., NURLU D., DEMİR S., KÖSTEK O., KARAMUSTAFAOĞLU Y. A., et al.
23. ULUSAL KANSER KONGRESİ, Antalya, Türkiye, 17 - 21 Nisan 2019, ss.272, (Özet Bildiri)
2019
201912. GERİATRİK (≥75 YAŞ), KASTRASYON DİRENÇLİMETASTATİK PROSTAT KANSERİ (KDMPK)HASTALARINDA 1. BASAMAK ANTİ- ANDROJENTEDAVİ SONUÇLARI- GERÇEK YAŞAM VERİSİ
ALKAN A., SEVGEN GÜÇ Z., GÜRBÜZ M., ÖZGÜN G., DEĞİRMENCİOĞLU S., DOĞAN M., et al.
23. ULUSAL KANSER KONGRESİ, Antalya, Türkiye, 17 - 21 Nisan 2019, ss.300, (Özet Bildiri)
2019
201913. Türkiye’de Yaşa Özgü Akciğer Kanseri İnsidans Oranları:Yaşlılarda Akciğer Kanseri Artmaktadır
SARI M., KÖSTEK O.
Ulusal Akciğer Sağlığı Kongresi 2019, Antalya, Türkiye, 13 - 17 Mart 2019, ss.127-128, (Özet Bildiri)
2018
201814. Karaciğere Metastatik KolorektalKanserde ALBI Skorunun PrognostikÖnemi
DEMİRCAN N. C., KÖSTEK O.
2. Ulusal İmmünoterapi ve Onkoloji Kongresi • 31 Ekim - 4 Kasım 2018, Antalya, Antalya, Türkiye, 31 Ekim - 04 Kasım 2018, ss.18, (Özet Bildiri)
2018
201815. Metastatik Kolorektal Kanser Tedavisinde3. Basamak: Yeniden Kemoterapi VsRegorafenib
KÖSTEK O., HACIOĞLU M. B., SAKİN A., DEMİR T., SARI M., ÖZKUL Ö., et al.
2. Ulusal İmmünoterapi ve Onkoloji Kongresi, Antalya, Türkiye, 31 Ekim - 04 Kasım 2018, (Özet Bildiri)
2018
201816. CHANGES IN LEAN BODY MASS AND SKELETAL MUSCLEAREA DURING PAZOPANIB VS SUNITINIB THERAPY FORMETASTATIC RENAL CANCER
KÖSTEK O., Yılmaz E., DEMİRCAN N. C., GÖKYER A.
2 nd International Congress on Oncological Sciences, Antalya, Türkiye, 20 - 23 Eylül 2018, ss.98-99, (Tam Metin Bildiri)
2018
201817. METASTATİK KOLOREKTAL KANSERLERDE REGORAFENİB ETKİNLİĞİ SAĞ-SOL FARKI VAR MI?
HACIOĞLU M. B., KÖSTEK O.
TREATMENT MODALITIES FOR STAGE IV DISEASES FOR COLORECTAL CANCER 6 th MEETING, İstanbul, Türkiye, 11 - 12 Mayıs 2018, (Özet Bildiri)
2018
201818. Can we predict the timing of hepatospecific contrast agent appearance in the bile duct before MRI?
Yılmaz E., KÖSTEK O.
Turkish society of magnetic resonance 23rd annual meeting, Ankara, Türkiye, 10 - 12 Mayıs 2018, cilt.50, ss.137, (Özet Bildiri)
2018
201819. Frequency of malignancy in radiologic imaging in Type 2 DM patients: preliminary findings
Yılmaz E., KÖSTEK O.
7th International Trakya Family Medicine Congress, Edirne, Türkiye, 21 - 25 Mart 2018, ss.122-124, (Tam Metin Bildiri)
2018
201820. Malign melanom hastalarında pineal gland kalsifikasyonu sıklık ve prognoz ile ilişkisi
Yılmaz E., KÖSTEK O.
Türk Nöroradyoloji Derneği 27. yıl yıllık toplantısı nöroradyoloji ve baş-boyun radyolojisi, İstanbul, Türkiye, 16 - 18 Şubat 2018, ss.24, (Özet Bildiri)
2017
201721. THE EFFECT OF ACITRETIN TREATMENT ON PITUITARY HORMONES IN PSORIASIS VULGARIS: A NONCONTROLLED STUDY
KARADAĞ A. S., ÖZLÜ E., KÖSTEK O., GÜNEŞ BİLGİLİ S., BALAHAROĞLU R., ERTUĞRUL D. T.
2nd International Dermatology and Cosmetology Congress, 15 - 18 Mart 2017, (Özet Bildiri)
2016
201622. Serum Gas 6 and omentin levels and relationship with flow mediated dilatation, aortic distensibility, left ventricule mass index and disease severity in patients with psoriasis
Toprak A. E., Karadag A. S., ERMAN H., Aksu F., Ustunbas T. K., Kostek O., et al.
41st FEBS Congress on Molecular and Systems Biology for a Better Life, Kusadasi, Türkiye, 3 - 08 Eylül 2016, cilt.283, ss.111, (Özet Bildiri)
2016
201623. Endocan: A Novel Predictor of Endothelial Dysfunction in Obstructive Sleep Apnea Syndrome
Kanbay A., Ceylan E., ÇALIŞKAN M., Telci O., Kostek O., Erek A., et al.
CHEST World Congress, Shanghai, Çin, 15 - 17 Nisan 2016, cilt.149, (Özet Bildiri)
2015
201524. The effects of serum klotho levels on endothelial function and early atherosclerosis predictors in healty population
Keles N., Caliskan M., Dogan B., Keles N. N., Aksu F., Kostek O., et al.
Congress of the European-Society-of-Cardiology (ESC), London, Kanada, 29 Ağustos - 02 Eylül 2015, cilt.36, ss.581-582, (Özet Bildiri)
2014
201425. Functioning beta cells in type 1 diabetes may not be as low as it is presumed
TAMER H. G., DOĞAN B., OCAKOĞLU İ., KÖSTEK O., İLKAY K., SAĞUN H. G., et al.
50th EASD Annual Meeting, VİYANA, Avusturya, 15 - 19 Eylül 2014, cilt.57, ss.189, (Özet Bildiri)
2014
201426. A Pathophysiological Link: Monocyte Count and LDL CholesterolLevels
TELCİ ÇAKLILI Ö., KÖSTEK O., ÖZTÜRK E., OĞUZ A.
10th INTERNATIONAL CONGRESS OF UPDATE IN CARDIOLOGYAND CARDIOVASCULAR SURGERY, 13 - 16 Mart 2014, cilt.113, ss.14, (Özet Bildiri)
2013
201327. Diabetes mellitus knowledge of nurses
YAVUZ G., OĞUZ A., TELCİ ÇAKLILI Ö., KÖSTEK O.
10th MetabolicSyndrome Symposium, Antalya, Türkiye, 5 - 08 Eylül 2013, cilt.15, ss.235, (Özet Bildiri)
2013
201328. Obesity is the main culprit in polycysticovary syndrome?
KESKİN H., ÇARLIOĞLU A., KARAKILIÇ ULUDAĞ E. Ü., KABİL KUCUR S., GÖZÜKARA İ., KAYA Y., et al.
10th MetabolicSyndrome Symposium, Antalya, Türkiye, 5 - 08 Eylül 2013, cilt.15, ss.271, (Özet Bildiri)
2013
201329. Does individualized education on diabetes improveglycemic control?
TELCİ ÇAKLILI Ö., ÖZATA M., ARSLAN BAHADIR M., KÖSTEK O., OĞUZ A.
10th MetabolicSyndrome Symposium, Antalya, Türkiye, 5 - 08 Eylül 2013, cilt.15, ss.241, (Özet Bildiri)
2013
201330. Diabetes risk awareness of general population
FEYİZOĞLU G., DOĞAN B., FEYİZOĞLU H., TELCİ ÇAKLILI Ö., KÖSTEK O., OĞUZ A.
10th MetabolicSyndrome Symposium, Antalya, Türkiye, 5 - 08 Eylül 2013, cilt.15, ss.235, (Özet Bildiri)
2013
201331. The Impact of Non-Cardiac Surgery on Electrocardiograph Changes, Troponin Levels in patients with Intermediate and High Risk According to Framingham General Cardiovascular Disease Risk Score
KESKİNLER M. V., Bulur S., Kostek O., Erok B., Can O., Danacioglu Y. O., et al.
29th Turkish Cardiology Congress of the Turkish-Society-of-Cardiology (TSC) with International Participation, Antalya, Türkiye, 26 - 29 Ekim 2013, cilt.62, (Özet Bildiri)
2013
201332. Association between toll-like receptor 4polymorphism and type 2 diabetes mellitus
MESCİ B., EREN P., KIZILTAŞ Ş., OĞUZ A., TUNCER İ., KÖSTEK O., et al.
15th European Congress of Endocrinology, 27 Nisan - 01 Mayıs 2013, cilt.32, ss.372, (Özet Bildiri)
2012
201233. Serum and Pleural NTproBNP Levels In Patients with Congestive Heart Failure and Its Contribution to Diagnosis
Arpag H., Kuyucu T., Ordu E. N., Karabay C. Y., OĞUZ A., MESCİ B., et al.
3rd World Heart Failure Congress, İstanbul, Türkiye, 29 Kasım - 02 Aralık 2012, cilt.30, ss.88, (Özet Bildiri)
2012
201234. Metabolic evaluation of patients with Behcet’sdisease
MESCİ B., OĞUZ A., KAVALA M., İŞBİLEN B., İŞMAN F. K., SADIGOV F., et al.
9th MetabolicSyndrome Symposium, Antalya, Türkiye, 5 - 08 Nisan 2012, cilt.13, ss.651, (Özet Bildiri)
2012
201235. Nutritional perception and practice differences indieting
KÖSTEK O., OĞUZ A., MESCİ B., ATEŞ M., GENÇTURK N., TELCİ ÇAKLILI Ö., et al.
9th MetabolicSyndrome Symposium, Antalya, Türkiye, 5 - 08 Nisan 2012, cilt.13, ss.652, (Özet Bildiri)
2012
201236. Prevalence of abdominal obesity, high bloodpressure and dysglycaemia in hospitalizedpatients
OĞUZ A., MESCİ B., GENCTURK N., ULUS C., ATEŞ M., KÖSTEK O., et al.
9th MetabolicSyndrome Symposium, Antalya, Türkiye, 5 - 08 Nisan 2012, cilt.13, ss.653, (Özet Bildiri)
2012
201237. Extra foods and drinks of diabetic patients in thehospital
MESCİ B., OĞUZ A., GENCTURK N., ATEŞ M., ULUS C., TELCİ ÇAKLILI Ö., et al.
9th MetabolicSyndrome Symposium, Antalya, Türkiye, 5 - 08 Nisan 2012, cilt.13, ss.652, (Özet Bildiri)
2012
201238. The problems of oral anticoagulation in patientswith metabolic syndrome, hypertension ordiabetes mellitus
MESCİ B., AGURASLAN E., KARACA M., ZENGİN A., TUSUN E., KÖSTEK O., et al.
9th Metabolic Syndrome Symposium, Antalya, Türkiye, 5 - 08 Nisan 2012, cilt.13, ss.650, (Özet Bildiri)
Bilimsel Kuruluşlardaki Üyelikler / Görevler
2019 - Devam Ediyor
2019 - Devam EdiyorASCO
Üye
2019 - Devam Ediyor
2019 - Devam EdiyorESMO
Üye
2016 - Devam Ediyor
2016 - Devam Ediyor